Classification
Compound class	Synthetic organic

IUPAC Name

2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f]-[1, 2, 4] triazolo [4,3-a] [1, 4] diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide dehydrate

International Nonproprietary Names
INN number	INN
10407	birabresib

Synonyms

MK-8628 | OTX-015 | OTX015

Database Links
CAS Registry No.	202590-98-5 (source: WHO INN record)
GtoPdb PubChem SID	252166571
PubChem CID	9936746
Search Google for chemical match using the InChIKey	GNMUEVRJHCWKTO-FQEVSTJZSA-N
Search Google for chemicals with the same backbone	GNMUEVRJHCWKTO
Search PubMed clinical trials	birabresib
Search PubMed titles	birabresib
Search PubMed titles/abstracts	birabresib
Search UniChem for chemical match using the InChIKey	GNMUEVRJHCWKTO-FQEVSTJZSA-N
Search UniChem for chemicals with the same backbone	GNMUEVRJHCWKTO

Comments

OTX015 inhibits interaction between bromodomain and extra-terminal (BET) family of bromodomain-containing proteins (BRDs) BET domains and acetylated histone 4 (AcH4). It is an orally available novel BRD2/3/4 inhibitor with potent preclinical anti-tumour activity [1,4,6,10,12-13]. OTX015 is an analogue of (+)-JQ1.